We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical and molecular features of Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma: Results in a multi‐center trial.
- Authors
Zhao, Chen Xing; Wen, Jing Jing; Fu, Di; Xu, Peng Peng; Cheng, Shu; Wang, Li; Wang, Chao Fu; Fei, Xiao Chun; Wang, Xin; Zhou, Jian Feng; Su, Li Ping; Chen, Zhuo Wen; Chen, Jie Ping; Fang, Mei Yun; Liu, Ting; Song, Yong Ping; Yu, Kang; Li, Yan; Gu, Jian; Hou, Ming
- Abstract
Gene mutations were first screened in 180 patients with WGS/WES/targeted sequencing data, including 40 cases of EBER-positive DLBCL and 140 cases of EBER-negative DLBCL. As serum EBV DNA is mostly derived from tumor cells,6 our findings emphasized the advantage of serum EBV DNA as noninvasive biomarker for predicting tumor EBER status and prognostic factor of DLBCL. Epstein-Barr virus (EBV) is an important human oncogenic virus and closely related to the pathogenesis of diffuse large B-cell lymphoma.1 This is, to our knowledge, the first study to systematically evaluate the clinical impact of EBV infection on DLBCL, based on a prospective clinical trial (NHL-001, NCT01852435).
- Subjects
DIFFUSE large B-cell lymphomas; RITUXIMAB; T cells; CYTOTOXIC T cells; B cell lymphoma
- Publication
Clinical & Translational Medicine, 2021, Vol 11, Issue 9, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.539